Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC).

3567 Background: EGFR directed therapy is limited by mutations in KRAS or BRAF; however, the search for other predictive biomarkers is critical (Clin Cancer Res, 2008; 68: 1953). In our study, we e...